Skip to main content
Premium Trial:

Request an Annual Quote

LSBC, Icon Genetics in Biomanufacturing Deal with Ukrainian Government

NEW YORK, Dec. 3-Large Scale Biology Corporation and Germany's Icon Genetics have signed an agreement with the Ukrainian government to develop plant-produced pharmaceuticals, LSBC said in a statement today.


The two companies plan to work with Ukrainian scientists to develop transgenic plants that can produce pharmaceutical quality proteins.


The Vice Prime Minister of Ukraine, Volodymyr Seminozhenko, signed a letter of intent with the two companies on November 5th, according to LSBC.


LSBC is developing a biomanufacturing process, Geneware, and claims to have built the world's first commercial scale plant pharmaceutical production center.


Icon Genetics, based in Munich, is working on agricultural biotechnology techniques.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.